Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2009 Feb;14(3-4):214-22. doi: 10.1016/j.drudis.2008.11.013. Epub 2009 Jan 17.

Targeting virulence: a new paradigm for antifungals.

Author information

1
Department of Dermatology and Allergology, Ludwig-Maximilian-University Munich, Frauenlobstrasse 9-11, 80337 Munich, Germany.

Abstract

In the recent past, we have found ourselves in need of truly novel antifungal drugs as drug resistance in fungi has been evolving. Moreover, effective therapy has become particularly important as the number of immuno-compromised patients with life-threatening fungal infections increases. Fortunately, during the last few years, virulence factors of fungi and their inhibitors have, at least to some extent, been discovered and characterized. This should provide new options for the development of potential antifungal therapeutics. Inhibitors of the secreted aspartic proteinase of Candida albicans might turn out to be particularly rewarding.

PMID:
19152839
DOI:
10.1016/j.drudis.2008.11.013
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center